Benefits of the contract
The LPP monitors the use of multiple sclerosis medicines, where there are price changes, or at the end of the patent, when generic versions become available. The volumes are taken from IQVIA and Define databases. The contract is owned by the Commercial Medicines Unit.
Applicable to all London trusts providing services for multiple sclerosis.